Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
AstraZeneca
Johnson and Johnson
Moodys

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

ZYPREXA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Zyprexa, and what generic alternatives are available?

Zyprexa is a drug marketed by Lilly and Eli Lilly Co and is included in four NDAs.

The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Drug patent expirations by year for ZYPREXA
Drug Prices for ZYPREXA

See drug prices for ZYPREXA

Drug Sales Revenue Trends for ZYPREXA

See drug sales revenues for ZYPREXA

Recent Clinical Trials for ZYPREXA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of ArizonaPhase 1
Sidney R. Baer, Jr. FoundationPhase 1
Impel NeuroPharma Inc.Phase 1

See all ZYPREXA clinical trials

Recent Litigation for ZYPREXA

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALCON MANUFACTURING, LTD v. APOTEX INC.2006-11-15
Bayer AG v. Dr. Reddy's Lab.Ltd.2004-03-24
ELI LILLY AND COMPANY v. ZENITH GOLDLINE PHARMACEUTICALS, INC.

See all ZYPREXA litigation

Pharmacology for ZYPREXA
Paragraph IV (Patent) Challenges for ZYPREXA
Tradename Dosage Ingredient NDA Submissiondate
ZYPREXA TABLET;ORAL olanzapine 020592

US Patents and Regulatory Information for ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ZYPREXA olanzapine INJECTABLE;INTRAMUSCULAR 021253-001 Mar 29, 2004 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-006 Sep 9, 1997 AB RX Yes No   Start Trial   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-003 Sep 30, 1996 AB RX Yes No   Start Trial   Start Trial   Start Trial
Lilly ZYPREXA ZYDIS olanzapine TABLET, ORALLY DISINTEGRATING;ORAL 021086-002 Apr 6, 2000 AB RX Yes No   Start Trial   Start Trial   Start Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZYPREXA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-004 Sep 30, 1996   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-004 Sep 30, 1996   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-003 Sep 30, 1996   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996   Start Trial   Start Trial
Lilly ZYPREXA olanzapine TABLET;ORAL 020592-002 Sep 30, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Dow
Johnson and Johnson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.